Rituximab serum concentrations during immuno-chemotherapy of follicular lymphoma correlate with patient gender, bone marrow infiltration and clinical response

BACKGROUND: Treatment of follicular lymphoma with rituximab is currently recommended at a dose of 375 mg/m(2). We aimed to provide a rationale for optimal dosing and scheduling of this anti-CD20 antibody based on pharmacokinetics. DESIGN AND METHODS: Clinical efficacy of immunochemotherapy with ritu...

Πλήρης περιγραφή

Αποθηκεύτηκε σε:
Λεπτομέρειες βιβλιογραφικής εγγραφής
Κύριοι συγγραφείς: Jäger, Ulrich, Fridrik, Michael, Zeitlinger, Markus, Heintel, Daniel, Hopfinger, Georg, Burgstaller, Sonja, Mannhalter, Christine, Oberaigner, Wilhelm, Porpaczy, Edit, Skrabs, Cathrin, Einberger, Christine, Drach, Johannes, Raderer, Markus, Gaiger, Alexander, Putman, Monique, Greil, Richard
Μορφή: Artigo
Γλώσσα:Inglês
Έκδοση: Ferrata Storti Foundation 2012
Θέματα:
Original Articles and Brief Reports
Διαθέσιμο Online:https://ncbi.nlm.nih.gov/pmc/articles/PMC3436246/
https://ncbi.nlm.nih.gov/pubmed/22511498
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3324/haematol.2011.059246
Ετικέτες: Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!

Παρόμοια τεκμήρια